Lead Product(s) : Darigabat
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Darigabat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Panic Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : Darigabat
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CVL-865 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Seizures.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 29, 2020
Lead Product(s) : Darigabat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Darigabat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Darigabat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darigabat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Darigabat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2023
Lead Product(s) : Darigabat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darigabat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Darigabat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Darigabat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a live webcast, Cerevel will lead an in-depth discussion of darigabat, formerly CVL-865, its Phase 2 GABA positive allosteric modulator (PAM) and provide an overview of the PDE4B inhibitor and kappa opioid receptor (KOR) agonist preclinical programs.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2021
Lead Product(s) : Darigabat
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CVL-865 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Panic Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Darigabat
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cerevel Therapeutics Dosed First Patient in Phase 2 Trial of CVL-865 for the Treatment of Epilepsy
Details : The randomized, double-blind, placebo-controlled, parallel group Phase 2 study will assess the efficacy, safety and tolerability profile of CVL-865 as an adjunctive treatment in patients with drug-resistant focal onset seizures.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2020
Details : CVL-865 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Seizures.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2020
Reset All
